

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 July 2023 (20.07.2023)



(10) International Publication Number
WO 2023/135428 A1

(51) International Patent Classification:

A61K 38/48 (2006.01) A61K 47/02 (2006.01)
A61K 8/66 (2006.01) A61K 47/18 (2006.01)
A61K 9/00 (2006.01) A61Q 19/08 (2006.01)

(21) International Application Number:

PCT/GB2023/050061

(22) International Filing Date:

13 January 2023 (13.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/299,705 14 January 2022 (14.01.2022) US
63/399,127 18 August 2022 (18.08.2022) US

(71) Applicants: **GALDERMA HOLDING SA** [CH/CH];
Zählerweg 10, 6300 Zug (CH). **IPSEN BIOPHARM
LIMITED** [GB/GB]; Unit 9, Ash Road, Wrexham Indus-
trial Estate, Wrexham LL13 9UF (GB).

(72) Inventors: **AXEN, Eva**; c/o Galderma Holding SA, Zähler-
weg 10, 6300 Zug (CH). **LIN, Xiaoming**; c/o Galderma
Holding SA, Zählerweg 10, 6300 Zug (CH). **WEINBERG,
Felipe**; c/o Galderma Holding SA, Zählerweg 10, 6300 Zug
(CH). **MAGUIRE, Courtney**; c/o Galderma Holding SA,
Zählerweg 10, 6300 Zug (CH). **NILSSON, Anna**; c/o Gal-
derma Holding SA, Zählerweg 10, 6300 Zug (CH).

(74) Agent: **MACLEAN, Martin Robert**; Mathys & Squire,
The Shard, 32 London Bridge Street, London SE1 9SG
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES

FIG. 5

		GM-1114-DP (N = 222)		Placebo (N = 75)	
Preferred Term		Intensity	Subjects / Events	Subjects / Events	
Headache		Total	5 (2.3%) / 5	0 / 0	
		Mild	2 (0.9%) / 2		
		Moderate	3 (1.4%) / 3		
		Severe	0		
Eyelid Ptosis		Total	2 (0.9%) / 2	0 / 0	
		Mild	2 (0.9%) / 2		
		Moderate	0		
		Severe	0		
Injection Site Bruising		Total	1 (0.5%) / 1	0 / 0	
		Mild	1 (0.5%) / 1		
		Moderate	0		
		Severe	0		

N= number of subjects in safety population
There were no adverse events that lead to premature study discontinuation.

(57) Abstract: Disclosed herein are methods of treatment of glabellar lines and lateral canthal lines using liquid botulinum neurotoxin compositions.

WO 2023/135428 A1